NO20082942L - Ligander som binder IL-4 og/eller IL-13 - Google Patents

Ligander som binder IL-4 og/eller IL-13

Info

Publication number
NO20082942L
NO20082942L NO20082942A NO20082942A NO20082942L NO 20082942 L NO20082942 L NO 20082942L NO 20082942 A NO20082942 A NO 20082942A NO 20082942 A NO20082942 A NO 20082942A NO 20082942 L NO20082942 L NO 20082942L
Authority
NO
Norway
Prior art keywords
ligands
bind
interleukin
treatment
methods
Prior art date
Application number
NO20082942A
Other languages
English (en)
Inventor
Steve Holmes
Ian M Tomlinson
Philip D Drew
Rudolf M T De Wildt
Armin Sepp
Malgorzata Pupecka
Adriaan Allart Stoop
Inusha De Silva
Caroline J Dimech
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of NO20082942L publication Critical patent/NO20082942L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SAMMENDRAG Ligander som har bindingsspesifisitet for interleukin-4 (IL-4), for interleukin-13 (IL-13) eller for IL-4 og IL-13, er beskrevet. Også beskrevet er fremgangsmåter for anvendelse av disse ligandene. Spesielt er anvendelse av disse ligandene for behandling av allergisk astma beskrevet.
NO20082942A 2006-01-24 2008-07-02 Ligander som binder IL-4 og/eller IL-13 NO20082942L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76170806P 2006-01-24 2006-01-24
PCT/GB2007/000228 WO2007085815A2 (en) 2006-01-24 2007-01-24 Ligands that bind il-4 and/or il-13

Publications (1)

Publication Number Publication Date
NO20082942L true NO20082942L (no) 2008-10-15

Family

ID=38028503

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082942A NO20082942L (no) 2006-01-24 2008-07-02 Ligander som binder IL-4 og/eller IL-13

Country Status (16)

Country Link
US (3) US20110159003A1 (no)
EP (1) EP1976882A2 (no)
JP (2) JP2009523460A (no)
KR (1) KR20080098382A (no)
CN (1) CN101578298A (no)
AU (1) AU2007209202A1 (no)
BR (1) BRPI0710572A2 (no)
CA (1) CA2636854A1 (no)
CR (1) CR10179A (no)
EA (1) EA200801515A1 (no)
IL (1) IL192572A0 (no)
MA (1) MA30175B1 (no)
NO (1) NO20082942L (no)
TW (2) TW200740843A (no)
WO (1) WO2007085815A2 (no)
ZA (1) ZA200806202B (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
WO2009138413A1 (en) * 2008-05-15 2009-11-19 Domantis Limited Single domain antibodies that bind il-13
CA2651567A1 (en) * 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
WO2009030285A1 (en) * 2007-09-07 2009-03-12 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
EP2036980A1 (de) * 2007-09-14 2009-03-18 Gruber, Jens Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
AU2017201008B2 (en) * 2007-10-15 2018-12-13 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
US20100260853A1 (en) * 2007-12-13 2010-10-14 Amrik Basran Compositions for pulmonary delivery
EP2238165B1 (en) 2008-01-07 2017-07-05 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Anti-hiv domain antibodies and method of making and using same
NZ601815A (en) * 2008-03-31 2014-10-31 Genentech Inc Compositions and methods for treating and diagnosing asthma
US8217140B2 (en) 2008-04-17 2012-07-10 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
PL2334705T3 (pl) * 2008-09-26 2017-06-30 Ucb Biopharma Sprl Produkty biologiczne
TW201019962A (en) * 2008-10-21 2010-06-01 Domantis Ltd Ligands that have binding specificity for DC-SIGN
DK2356269T3 (en) 2008-10-31 2016-08-15 Janssen Biotech Inc FIBRONECTIN TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, PROCEDURES AND APPLICATIONS
KR20110092328A (ko) * 2008-11-26 2011-08-17 글락소 그룹 리미티드 Ｉｌ-13에 결합하는 리간드
US8858940B2 (en) 2008-12-10 2014-10-14 Ablynx N.V. Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
EA201190275A1 (ru) * 2009-05-28 2012-11-30 Глаксо Груп Лимитед Белок, связывающий интерлейкин-13 (il-13)
ES2729422T3 (es) 2009-05-28 2019-11-04 Glaxo Group Ltd Proteínas de unión al antígeno
SG177601A1 (en) * 2009-07-16 2012-02-28 Glaxo Group Ltd Improved anti-serum albumin binding single variable domains
IN2012DN00412A (no) * 2009-07-29 2015-05-22 Glaxo Group Ltd
AU2011212442A1 (en) 2010-02-05 2012-08-09 Ablynx Nv Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
WO2011098552A2 (en) 2010-02-11 2011-08-18 Ablynx Nv Methods and compositions for the preparation of aerosols
WO2011137319A2 (en) 2010-04-30 2011-11-03 Centocor Ortho Biotech Inc. Stabilized fibronectin domain compositions, methods and uses
MX2013007936A (es) 2011-01-06 2013-08-09 Glaxo Group Ltd Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta.
EP2686014A1 (en) 2011-03-16 2014-01-22 Sanofi Uses of a dual v region antibody-like protein
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
ES2664619T3 (es) 2011-04-21 2018-04-20 Bristol-Myers Squibb Company Polipéptidos de anticuerpos que antagonizan CD40
EP3540100B8 (en) 2011-09-27 2022-11-02 Janssen Biotech, Inc. Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces
US10481164B2 (en) * 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
EP2863948B1 (en) 2012-06-22 2018-10-24 Cytomx Therapeutics Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
WO2014031610A1 (en) 2012-08-21 2014-02-27 Sanofi Methods for treating or preventing asthma by administering an il-4r antagonist
CN113234142B (zh) * 2012-08-22 2024-03-05 财团法人牧岩生命工学研究所 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
CA2934004C (en) * 2013-12-17 2023-07-04 The Metrohealth System Compositions and methods for treating fatty tissue buildup
US11066467B2 (en) 2013-12-17 2021-07-20 Mhs Care-Innovation Llc Compositions and methods for treating ischemic heart disease
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by adding an IL-4R antagonist
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
CA2943326A1 (en) 2014-04-11 2015-10-15 Novartis Ag Methods of selectively treating asthma using il-13 antagonists
CA2963037A1 (en) 2014-10-10 2016-04-14 Ablynx N.V. Treatment of rsv infection
AU2015329935B2 (en) 2014-10-10 2019-09-19 Ablynx N.V. Inhalation device for use in aerosol therapy of respiratory diseases
CA2967602A1 (en) 2014-11-14 2016-05-19 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
JP6862343B2 (ja) 2014-12-19 2021-04-21 アブリンクス エン．ヴェー． システイン結合ナノボディダイマー
JP2019523213A (ja) 2016-05-02 2019-08-22 アブリンクス エン．ヴェー． Ｒｓｖ感染の処置
JP6293829B2 (ja) * 2016-08-05 2018-03-14 モガム インスティチュート フォー バイオメディカル リサーチＭＯＧＡＭ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
WO2018111973A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd8a-binding fibronectin type iii domains
CA3079946A1 (en) 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
CN108855003B (zh) * 2018-06-28 2021-01-05 南开大学 一种用于清除血液中炎性因子的免疫吸附剂及其制备方法
CN111518211B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 抗人白介素4受体α单克隆抗体的制药用途
WO2020176815A2 (en) * 2019-02-27 2020-09-03 Zhejiang Nanomab Technology Center Co. Ltd. Sequence-based high throughput method generating camelids antibodies to cover broad epitopes with high-resolution
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
JP2022551204A (ja) 2019-10-14 2022-12-07 アロ・バイオセラピューティクス・カンパニー Ｃｄ７１結合フィブロネクチンｉｉｉ型ドメイン
CN113527488A (zh) 2020-04-22 2021-10-22 迈威(上海)生物科技股份有限公司 一种靶向人程序性死亡配体1（pd-l1）的单可变域抗体及其衍生物
JP2023524997A (ja) * 2020-05-06 2023-06-14 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｌｅｃ１２ａを標的とする抗体及びその使用
IL307582A (en) 2021-04-14 2023-12-01 Aro Biotherapeutics Company CD71-binding domains of the fibronectin type
US20240117030A1 (en) * 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
WO2024038112A1 (en) * 2022-08-17 2024-02-22 Institut National de la Santé et de la Recherche Médicale Improved anti-albumin nanobodies and their uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
KR0158240B1 (ko) * 1992-02-19 1998-11-16 에릭 에스. 딕커 사람 인터루킨-4에 대한 사람화 모노클로날 항체의 클로닝 및 발현
US5596072A (en) * 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US7175988B2 (en) * 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
JP2006523090A (ja) * 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
ES2967485T3 (es) * 2003-12-23 2024-04-30 Genentech Inc Nuevos anticuerpos anti-IL 13 y usos de los mismos
ATE395358T1 (de) * 2004-02-27 2008-05-15 Regeneron Pharma Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
WO2006023460A2 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY

Also Published As

Publication number Publication date
EA200801515A1 (ru) 2009-02-27
IL192572A0 (en) 2009-02-11
WO2007085815A3 (en) 2007-11-15
US20090060916A1 (en) 2009-03-05
TW200804593A (en) 2008-01-16
EP1976882A2 (en) 2008-10-08
BRPI0710572A2 (pt) 2013-01-08
MA30175B1 (fr) 2009-01-02
JP2009523459A (ja) 2009-06-25
US20120093830A1 (en) 2012-04-19
JP2009523460A (ja) 2009-06-25
ZA200806202B (en) 2009-11-25
CN101578298A (zh) 2009-11-11
CA2636854A1 (en) 2007-08-02
WO2007085815A2 (en) 2007-08-02
WO2007085815A8 (en) 2008-07-31
US20110159003A1 (en) 2011-06-30
TW200740843A (en) 2007-11-01
CR10179A (es) 2008-10-29
AU2007209202A1 (en) 2007-08-02
KR20080098382A (ko) 2008-11-07

Similar Documents

Publication Publication Date Title
NO20082942L (no) Ligander som binder IL-4 og/eller IL-13
NO20085422L (no) Bindingsproteiner for hepatocyttvekstfaktor (HGF)
NO20085421L (no) Bindingsproteiner for hepatocyttvekstfaktor (HGF)
CY1117942T1 (el) Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april)
NO20070189L (no) Immunoglobuliner
MX2009006471A (es) Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
DK1742966T3 (da) Antistoffer og molekyler afledt deraf som binder til STEAP-1 proteiner
NO20076046L (no) Bindemidler
NO20053114D0 (no) Astma og allergisk inflammasjonsmodulatorer.
NO20091181L (no) Anti-C5AR-antistoffer med forbedrede egenskaper
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
MX2010001779A (es) Peptidos para vacunas.
CR20140465A (es) Proteinas de union a interleuquina-13
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
MX2009010765A (es) Anticuerpos anti-ige.
MY162511A (en) Engineered anti-tslp antibody
NO20083720L (no) Fremgangsmater og sammensetninger for antagonisme av RAGE
NO20065536L (no) Behandling av astma hos barn
ATE469658T1 (de) Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung
BRPI0814761A2 (pt) composição, produção e uso de partículas sorventes para dessulfurização de gás de combustão
WO2009111450A3 (en) Metalloproteinase 9 binding proteins
WO2009111508A3 (en) Metalloproteinase 9 and metalloproteinase 2 binding proteins
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
DK2185574T3 (da) Antistoffer og relaterede molekyler, der bindes til 24P4C12-proteiner
MY150400A (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application